AT THE PEAK of the Covid-19 pandemic, the one thing that had become ubiquitous was the RT-PCR test. Scenes of swabs being thrust into the nose and throat had practically become part of regular life. What that also did was provide a fillip to the financials of diagnostic companies that were doing the tests. The possibility of a new revenue and profit stream also encouraged a herd of other entities to jump into the diagnostics fray. But now, as the pandemic wanes and RT-PCR testing peters to a trickle, the past few quarters have seen profits dip for leading diagnostic players. For example, market leader Dr Lal PathLabs, headquartered in New Delhi, recorded a 26.5 per cent dip in consolidated net profit to ₹61.3 crore in Q4FY22 from ₹83.4 crore in Q4FY21. Likewise, Mumbai-headquartered Metropolis Healthcare reported a 34.8 per cent decline in consolidated net profit at ₹39.99 crore in Q4FY22 compared to ₹61.35 crore in Q4FY21.
According to a report by Antique Stock Broking, margins reported during FY21 at the peak of Covid-19 will not be repeated anytime soon, plus there is other impact, too. “We expect negative operating leverage and return ratios such as return on capital employed (ROCE) to remain under check at 2526 per cent for both [Dr Lal and Metropolis], a decline in comparison to the pre-pandemic range of around 33 per cent,” says the report released in September. Another report from Credit Suisse, penned by research analysts Sayantan Maji and Anubhav Aggarwal, says that high competitive intensity could halve industry ROCE. The report says: “We expect ROCE to settle down to around 20-25 per cent by FY27E, implying Ebitda margin of around 20 per cent. Ebitda margin of Dr Lal and Metropolis has already declined by 300 bps (vs pre-Covid-19) to 23 per cent, but we expect it to steadily contract by a further 300-400 bps.”
Denne historien er fra October 30, 2022-utgaven av Business Today India.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra October 30, 2022-utgaven av Business Today India.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
"Moving to cloud helped us grow❞
What was the problem you were grappling with?
She's Got Time
MORE WOMEN ARE BECOMING WATCH CONNOISSEURS, SEEKING OUT BOTH JEWELLED AND TECHNICAL WATCHES FOR THEIR STYLE AND CRAFTSMANSHIP
RISING STAR
PARUL GULATI IS a name that's been steadily gaining prominence in the Indian entertainment industry after she appeared on season 2 of Shark Tank in 2023. She has become a multifaceted personality who effortlessly transitions between acting and entrepreneurship.
Building on a Legacy
WHEN ZAHABIYA KHORAKIWALA stepped into her role as Managing Director of Wockhardt Hospitals over a decade ago, she confronted formidable challenges that have since turned into achievements.
LEADER IN INNOVATION
AS FEDEX'S PRESIDENT (Middle East, Indian subcontinent and Africa), Kami Viswanathan has a lot on her plate.
WAITING IN THE WINGS
Here are those who missed out as they have not yet completed a year in office; they'll be strong contenders in 2025
A DECENT PROPOSAL
IN TODAY'S WORLD OF TRYING TO CREATE AN EQUITABLE SPACE, BOTH MEN AND WOMEN CONTRIBUTE TO THEIR HOUSEHOLDS. WOMEN ARE ENCOURAGED TO HAVE THEIR OWN SAVINGS POOL AND INVESTMENT ROUTINE. GIVEN THIS, HOW SHOULD FUTURE BRIDES APPROACH FINANCIAL PLANNING?
Women and the STEM Bias
EMPOWERING WOMEN IN STEM WILL NOT ONLY BENEFIT INDIVIDUALS, BUT ALSO STRENGTHEN THE ENTIRE INDUSTRY, DRIVING INNOVATION AND PROGRESS.
ROCKET WOMEN
WOMEN IN INDIA ARE NOT ONLY VENTURING INTO SPACE BUT ARE ALSO STARTING TO SPEARHEAD THE COUNTRY'S EFFORTS IN THE GLOBAL SPACE RACE.
ONE STEP FORWARD
THE NUMBER OF WOMEN INDEPENDENT DIRECTORS IS GROWING STEADILY, BUT IT'S A LONG WAY FROM GENDER PARITY. MUCH MORE NEEDS TO BE DONE TO BREAK THE GLASS CEILING IN BOARDROOMS.